Hepatic fibrosis. Role of matrix metalloproteases and TGFβ;Fibrosis hepática. El papel de las metaloproteinasas y deTGF-β

Gaceta Medica de Mexico

Volumn 141, Issue 4, 2005, Pages 315-322

  Sentíes Gómez, María Daniela ^a   Gálvez Gastélum, Francisco Javier ^a   Meza García, Eduardo ^a   Armendáriz Borunda, Juan ^a,b,c  

^a UNIVERSITY OF GUADALAJARA   (Mexico)

^b HOSPITAL CIVIL DE GUADALAJARA FRAY ANTONIO ALCALDE   (Mexico)

^c NONE   (Mexico)

Author keywords

Hepatic fibrosis; Metalloproteases; Transforming growth factor

Indexed keywords

GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; METALLOPROTEINASE; PLASMIN; PLASMINOGEN; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE; TRANSFORMING GROWTH FACTOR BETA; UROKINASE;

ALCOHOL ABUSE; CHRONIC HEPATITIS; DRUG PROTEIN BINDING; FIBRINOLYSIS; HUMAN; LIVER CIRRHOSIS; LIVER FIBROSIS; PROTEIN DEGRADATION; REVIEW;

ADULT; ANIMALS; ENZYME ACTIVATION; FIBRINOLYSIS; FORECASTING; HOMEOSTASIS; HUMANS; LIVER; LIVER CIRRHOSIS; MATRIX METALLOPROTEINASES; PLASMIN; PLASMINOGEN; PLASMINOGEN ACTIVATORS; TISSUE INHIBITOR OF METALLOPROTEINASES; TRANSFORMING GROWTH FACTOR BETA;

EID: 24344447348     PISSN: 00163813     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. Zakim D. in Fisiopatología: principios biológicos de la enfermedad (eds. Smith LH & Thier) 1138-1177 (Médica Panamericana, México, 1999).
2. Crispe NI. Hepatic cells and liver tolerance. Nature Rev Immunol 2003;3:51-62.
3. Geerts A. History heterogeneity developmental biology and functions of quiescent hepatic stellate cells. Semin Liv Dis 2001;21:311-335.
4. Friedman S. Liver fibrosis-from bench to beside. J of Hepatol 2003;38:s38-s53.
5. Friedman S, Michael A. Reversing hepatic fibrosis. Science & Medicine 2002;8:194-205.
6. Harrison EH. Symposium:Mechanistic aspects of vitamin and coenzyme utilization and function:A symposium in recognition of distinguished career of Dondald B.McCormik. Journal of Nutririon 2000;130:3403-3443.
7. Brinckerhoff C. Intersticial collagenases as a markers of tumor progression. Clin Cancer Res 2000;6:4823-4830.
8. Arthur MJ. Fibrogenesis II. Metalloproteases and their Inhibitors in liver fibrosis. Am J Physiol, Gastrointes Liver Physiol 2000;279:G245-G249.
9. Egeblad M, Zena W. New functions of the matrix metalloproteases in cancer progression. Nat Rev Cancer 2002;2:161-174.
10. www.rzpd.de/cards/index/htlm.
11. Murphy G, Stanton H, Cowell S, Butler G, Knäuper V, Atkinson S, et al. Mechanism for pro-matrix metalloprotease activation. APMIS 1999;107:38-44.
12. Westermark J, Kähäri VM. Regulation of matrix metalloproteases expression tumor invasion. FASEB J 1999;13:781-792.
13. Lijnen HR. Matrix metallorpotease and the cellyular fibrinolytic activity. Biochemistry (Moscow) 2002;67:107-115.
14. Wallon M & Christopher MO. The hemopexin like domain (C domain) of human gelatinase A (matrix metalloprotease -2) requires Ca2+ for fibronectin and heparin binding. JBC 1997;272:7473-7481.
15. Harold E, Van W, Henning BH. The cistyne switch. A principle of regulation of metalloproteases activity with potential applicability to the entire matrix metalloprotease gen Familiy. PNAS 1990;87:5578-5582.
16. Ramos De Simone N, Hahn-Dantona E, Hideaki Nagase JS, French DL, Quigley J. Activation of matrix metalloprotease -9 (MMP-9) a convering plasmin/stromelysin-1 cascade enhances tumor cell invation. JBC 1999;274:13066-13076.
17. Lijnen HR, Begona A, Berthe VH, Desiré C, Paul GD. Inactivation of Plasminogen Activator Inhibitor-1 by specific proteolisis with stromelysin-1 (MMP-3). JBC 2000;275:37645-37650.
18. Massagué J. Integration of Smad and MAPK pathways: a link and a linker revised. Genes Dev 2003;17:2993-2997.
19. Iredale J. Cirrhosis: new research provides a basis for rational and targeted treatments. British Medical Journal 2003;327:143-147.
20. Fujimoto J. Gene therapy for liver cirrhosis. J of Gastroenterol and Hepatol 2000;15:D33-D36.
21. http://www.SSA.gob.mx.
22. Bribiesca LB. La cirrosis hepática. ¿puede ser reversible? Acta Médica Grupo Ángeles 2003;1:37-39.
23. Olaso E, Fridman S. Molecular regulation of hepatic fibrogenesis. J of Hepatol 1998;29:836-847.
24. Roberts A. TGF-B signaling from receptors to the nucleus. Microbes and Infection 1999;1:1265-1273.
25. Vilchis-Landeros M, Juaréz P, López-Casillas F. El papel fisiopatológico del TGF-β en las nefropatías de diversas etiologías: los inhibidores del TGF-β como agentes terapéuticos potenciales. Gac Med Mex 2003;139:126-134.
26. López-Casillas F, Massagué J. TGF-B: receptores, señales y acciones. Gac Med Mex 2003;139:139-143.
27. Galvez-Gastelum FJ, Sandoval-Rodriguez A, Armendariz-Borunda J. El factor de crecimiento transformante B como blanco terapéutico. Salud Publica Mex 2004;46:
28. Border AW, Noble AN. TGF-B. Scientific American Science & Medicine 1995;2:68-77.
29. Peralta-Zaragoza O, Lagunas-Martinez A, Madrid-Marina V. Transforming growth factor beta-1: structure, function, and regulation mechanisms in cancer. Salud Publica Mex 2001;43:340-351.
30. Bissell M, Roulot D, George J. Transforming growth factor and the liver. Hepatol 2001;34:859-867.
31. Hernandez-Canaveral I, Gonzalez J, Lopez-Casillas F, Armendariz-Borunda J. Amplified expression of dominant-negative transforming growth factor-beta type II receptor inhibits collagen type I production via reduced Smad-3 activity. J Gastroenterol Hepatol 2004;19:380-387.
32. Caestecker M. The transforming growth factor-B superfamily of receptors. Cytokine Growth Factor Rev 2004;15:1-11.
33. Kondou H, Mushiake S, Etani Y, Moyoshi Y, Michigami T, Ozono K. A blocking peptide for transforming growth factor-B1 activation prevents hepatic fibrosis in vivo. J Hepatol 2003;39:742-748.
34. Armendariz-Borunda J. Transforming Growth Factor B gene expression is transiently enhanced at critical stage during liver regeneration after CCI4 treatment. Laboratory Investigation 1993;69:283-294.
35. Tsuchida K, Zhu Y, Silva S, Dunn SR, Sharma K. Role of Smad-4 on TGF-B induced extracellular matrix stimulation in mesangial cells. Kidney Int 2003;63:2000-2004.
36. Zhu H A, B. Regulation of transforming growrh factor B signaling. Mol Cell Biol Res Commun 2001;4:321-330.
37. Armendáriz Borunda J, Jeorme S, Andrew K, Raghow P. Regulation of TGF-B gene expresion in rat liver intoxicated with carbon tetrachloride. FASEB J 1990;4:215-221.
38. Armendáriz-Borunda J. Kupffer cells from carbon tetrachloride-injured rat livers produce chemotactic factors for fibbroblast and monocytes: the role of tumor necorsis factor -a. Hepatology 1991;14:895-900.
39. Eikmans M, BJJ, De Heer E, Brujin JA. ECM hoeostasis in renal diseases genomic approach. Journal of Pathology 2003;200:526-536.
40. Flavell GLR. Transforming growth factor -b in T cell biology. Nature Immunol Rev 2002;2:46-53.
41. Moustakas Aristidis SS, Heldin Carl-Henrik. Smad regulation in TGF-b signal transduction. Journal of Cell Seiencie 2001;114:4359-4369.
42. Massagué Joan WD. transcriptional control of the TGF-b/Smad signaling system. EMBO Journal 2000. p. 1745-1754.
43. Piek Ester H. C.-H. D. T. P. Specificity, diversity and regulation in TGF-b superfamiliy signaling. FSEB Journal 1999;13:2105-2124.
44. Iimuro Y, Nishio T, Morimoto T, Nitta T, Stefanovic B, Choi S, et al. Delivery of matrix metalloprotease-1 attenuates established liver fibrosis in the rat. Gastroenterology 2003;124:445-458.
45. García L, Hernández I, Sandoval A, Garcia J, Vera J, Grijalva G, et al. Pirfenidone effectively reverses experimental liver fibrosis. J Hepatol 2002;37:797-805.
46. García-Bañuelos J, Siller-López F, Aguilar-Córdova E, Armendáriz-Borunda J. Cirrhotic rat livers with extensive fibrosis can be transduced with clinical grade adenoviral vectors. Gene Ther 2002;9:127-134.
47. Siller-López F, García-Bañuelos J, Hasty K, Segura J, Ramos-Marquez M, Qoronfleh M, et al. Truncated active matrix metalloprotease-8 gene expression in HepG2 cells is active against native type I collagen. Journal of Hepatology 2000;33:758-763.
48. Siller-López F, Sandoval A, Salgado S, Salazar A, Bueno M, García J et al. Treatment with human metalloprotease-8 gene delivery ameliorates experimental rat liver cirrohsis. Gastroenterology 2004;126:1122-1133.
49. Alejandra Miranda, Ana Rosa Rincón, Silvia Salgado, José Vera-Cruz, Javier Gálvez, Ma Cristina Islas et al. Improved Effects of Viral Gene Delivery of human uPA plus Biliodigestive Anastomosis Induce Recovery from Experimental Biliary Cirrhosis. Molecular Therapy 2004; 9:
50. Salgado S, García J, Vera J, Siller F, Bueno M, Miranda A et al. Liver cirrhosis is reverted by urokinase-type Plasminogen Activator gene therapy. Mol Ther 2000;2:545-551.
51. Dooley S, Hamzavi J, Breitkopf K, Wiercinska E, Said H, Lorenzen J, et al. Smad-7 prevents activation of hepatic stellate cells and liver fibrosis in rats. Gastroenterology 2003;125:178-191.
52. Arias M, Sauer-Lehnen S, Treptau J, Janoschek N, Theuerkauf I, Buettner R et al. Adenoviral expression of a transforming growth factor B1 antisense mRNA is effective in preventing liver fibrosis in bile-duct ligated rats. BMC Gastroenterol 2003;3:1-12.
53. Armendáriz Borunda J, Galvez J, Segura A, Miranda A & Beas C. Combined hUPA plus MMP-8 gene therapy reverts cirrhosis and improves hepatic encephalopaty. Hepatology 2003;38:336A-337A.